4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

<< Return to Previous Page

February 1, 2000 Table of Contents

Treatment of Psoriasis: An Algorithm-Based Approach for Primary Care Physicians

ASHA G. PARDASANI, M.D., STEVEN R. FELDMAN, M.D., PH.D., and ADELE R. CLARK, P.A.-C., Wake Forest University School of Medicine, Winston-Salem, North Carolina
Am Fam Physician. 2000 Feb 1;61(3):725-733. See related patient information handout on psoriasis, written b y the authors of this article.

Psoriasis is characterized by red, thickened plaques with a silvery scale. The lesions vary in size and degree of inflammation. Psoriasis is categorized as localized or generalized, based on the severity of the disease and its overall impact on the patient's quality of life and well-being. Patient education about the disease and the treatment options is important. Medical treatment for localized psoriasis begins with a combination of topical corticosteroids and coal tar or calcipotriene. For lesions that are difficult to control with initial therapy, anthralin or tazarotene may be tried. The primary goal of therapy is to maintain control of the lesions. Cure is seldom achieved. If control becomes difficult or if psoriasis is generalized, the patient may benefit from phototherapy, systemic therapy and referral to a physician who specializes in the treatment of psoriasis.

Psoriasis affects about 2 percent of the U.S. population. In 1990, psoriasis was the reason for more than 1 million visits to physicians.1 In the past, the treatment of psoriasis was primarily managed by dermatologists; this disorder accounted for only 0.4 percent of skin-related visits to family physicians.2 The number of patients treated by family physicians, however, is likely to have steadily increased as more patients seek medical care of psoriasis from their primary care physicians. This article describes an algorithmic treatment approach for primary care physicians. The algorithm is based on treatment guidelines for psoriasis published by the American Academy of Dermatology,3 supplemented by a review of the medical literature. There currently are no evidence-based guidelines for the treatment of psoriasis. Because localized plaque psoriasis is the most common form, the algorithm focuses on the treatment of this type of psoriasis.

Diagnosis
The primary cause of psoriasis remains unknown. Abnormal epidermal cell kinetics and abnormal activation of immune mechanisms are thought to be the major contributors, and treatment may affect one or both of these mechanisms.4 Psoriasis is characterized by red, scaling plaques, ranging from only a few lesions to total involvement of the skin. The primary lesion is a well-demarcated erythematous plaque with a silvery scale. Characteristically, psoriasis is symmetrically distributed, with lesions frequently located on the ears, elbows, knees, umbilicus, gluteal cleft and genitalia (Figure 1). The joints (psoriatic arthritis), nails and scalp may also be affected.

www.aafp.org/afp/2000/0201/p725.html?printable=afp

1/12

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

FIGURE 1. Common areas of distribution of psoriasis. The lesions are usually symmetrically distributed and are characteristically located on the ears, elbows, knees, umbilicus, gluteal cleft and genitalia. The joints (psoriatic arthritis), nails and scalp may also be affected.

Psoriasis undergoes koebnerization, manifested by the appearance of lesions at sites of cutaneous trauma. Itching is the most common symptom,4 and extensive scratching can often lead to superimposed lichen simplex chronicus. In some patients, burning and pain may be the only symptoms. Psoriasis can be classified into four types: plaque-type psoriasis, guttate psoriasis, localized pustular psoriasis and generalized pustular psoriasis. (Table 1). The less common forms of psoriasis include pustular (localized and generalized) and erythrodermic variants. The most common form is plaque-type psoriasis (Figure 2). The scale itself is variable, ranging from a thick, massive scale, as is generally seen on the scalp, to no scale at all, as is generally seen in intertriginous or partially treated areas.
TABLE 1.

Types of Psoriasis, Associated Findings and Treatment Options

Type of psoriasis Plaque-type psoriasis Clinical features Red, thick, scaly lesions with silvery scale Precipitating Differential factors diagnosis Stress, infection, trauma, medications, xerosis Atopic dermatitis, irritant dermatitis, cutaneous T-cell lymphoma, pityriasis rubra pilaris, seborrheic dermatitis Treatment options Localized: topical therapy with corticosteroids, calcipotriene (Dovonex), coal tars, anthralin (AnthraDerm) or tazarotene (Tazorac). Generalized:
2/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

phototherapy, systemic agents, combination therapy Guttate psoriasis Teardrop-shaped, pink to salmon, scaly plaques; usually on the trunk, with sparing of palms and soles Erythematous papules or plaques studded with pustules; usually on palms or soles (known as palmoplantar pustular psoriasis) Streptococcal Pityriasis rosea, Ultraviolet B throat secondary phototherapy, infection syphilis, drug natural sunlight eruption Stress, infection, medications Pustular drug eruption, dyshidrotic eczema, subcorneal pustular dermatosis Pustular drug eruption, subcorneal pustular dermatosis Drug eruption, eczematous dermatitis, mycosis fungoides, pityriasis rubra pilaris Same as for plaquetype psoriasis

Pustular psoriasis, localized

Pustular psoriasis, generalized

Same as localized with a more general involvement; may be associated with systemic symptoms such as fever, malaise and diarrhea; patient may or may not have had preexisting psoriasis

Stress, infection, medications

Systemic therapy and/or hospitalization usually required

Erythrodermic Severe, intense, generalized psoriasis erythema and scaling covering entire body; often associated with systemic symptoms; may or may not have had preexisting psoriasis

Stress, infection, medications

Systemic therapy and/or hospitalization usually required

FIGURE 2. A primary lesion of plaque-type psoriasis. The typical lesion is a well-demarcated, thick, erythematous plaque with a silvery scale.

Guttate psoriasis is characterized by numerous small, oval (teardrop-shaped) lesions that develop after an acute upper respiratory tract infection. These lesions are often not as scaly or as red as the classic lesions of plaque-type psoriasis. Usually, guttate psoriasis must be differentiated from pityriasis rosea, another condition characterized by the sudden outbreak of red scaly lesions. Compared with pityriasis rosea, psoriatic lesions are thicker and scalier, and the lesions are not usually distributed along skin creases. The diagnosis of psoriasis can usually be made on the basis of the clinical presentation; histologic confirmation is rarely needed. If the diagnosis is uncertain, a biopsy can be performed or consultation with a dermatologist can be obtained.
www.aafp.org/afp/2000/0201/p725.html?printable=afp 3/12

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

POST-DIAGNOSIS PATIENT EDUCATION

Once the diagnosis of psoriasis is made, patient education about the disease should begin. Points that should be emphasized about the disease initially include its noncontagious nature and the possibility of controlling but not curing it. Patients should also be assured that psoriasis is quite common. Exacerbating factors should be discussed, including stress, infection, trauma, xerosis and use of medications such as angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, lithium and the antimalarial agent hydroxychloroquine (Plaquenil). The National Psoriasis Foundation is a widely used resource for patients (Web site: http://www.psoriasis.org).

Topical Therapy
An algorithm for the treatment of localized psoriasis is depicted in Figure 3 . Localized psoriasis can be defined as disease that is limited to such a degree that topical therapy controls it. Generalized psoriasis may require oral medications, treatment with ultraviolet light or treatment at an outpatient or inpatient facility.

Treatment of Localized Psoriasis

www.aafp.org/afp/2000/0201/p725.html?printable=afp

4/12

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

FIGURE 3. Algorithm for the treatment of localized psoriasis. Treatment of localized psoriasis is initiated using topical corticosteroids, alone or in combination with coal tar or calcipotriene. Patients with resistant lesions may benefit from the addition of anthralin or tazarotene.

The treatment of psoriasis requires an understanding of the effect that psoriasis is having on the patient's quality of life, and that effect is extremely variable. Taking the individual patient's treatment needs into consideration can improve the overall outcome. Topical therapy, including corticosteroids, calcipotriene (Dovonex), coal tar products, tazarotene (Tazorac) and anthralin (Anthra-Derm), is the mainstay of treatment for localized disease (Tables 2 and 3). While the use of emollients should be encouraged, they should be used selectively because many (e.g., products containing lactic acid or alpha-hydroxy acids) can be irritating to inflamed or broken skin.
TABLE 2.

Profiles of Topical Agents Used in the Treatment of Psoriasis

Atrophy, HPA
www.aafp.org/afp/2000/0201/p725.html?printable=afp 5/12

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

Topical agent

axis Inconvenience effect* +

Skin Staining irritation Hypercalcemia Comments +/

Emollients (Moisturel, + Cetaphil, Curel, Nivea, etc.) Low-potency corticosteroids (classes 6 and 7), such as desonide (Desowen), aclometasone dipropionate (Aclovate); hydrocortisone agents (Cortizone, Cortaid, etc.) Medium-potency corticosteroids (classes 3, 4 and 5), such as triamcinolone acetonide (Kenalog), hydrocortisone valerate (Westcort), fluticasone propionate (Cutivate), halcinonide (Halog), mometasone furoate (Elocon) +

++

Duration of safe use unknown

High-potency + corticosteroids (classes 1 and 2), such as halobetasol propionate (Ultravate), clobetasol propionate (Temovate), diflorasone diacetate (Psorcon), betamethasone dipropionate (Diprolene), clobetasole propionate (Cormax) Topical calcipotriene (Dovonex) +

+++

Super-high potency safe for up to 4 weeks

+ at 120 g per week

Safe for up to 52 weeks; pregnancy category C

Coal tar preparations ++ (Estar gel, Balnetar, MG271, Neutrogena T/Gel, DHS Tar) Anthralin (Anthra-Derm, Drithocreme, Dritho-Scalp, Miconal) Tazarotene (Tazorac) +++

++

+++

++

+++

Pregnancy category X

OTC = over-the-counter; = not an ob served side effect; + = mild effect; ++ = moderate effect; +++ = severe effect. *Other potential side effects associated with corticosteroids include folliculitis, telangiectasia, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, striae, miliaria, glycosuria, hyperglycuria and manifestations of Cushing's syndrome. Side effects increase with increased potency, duration of therapy and total dosage.
www.aafp.org/afp/2000/0201/p725.html?printable=afp 6/12

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

TABLE 3.

Treatment of Psoriasis in Problem Areas

Site Scalp Special problem Hair-bearing areas are not receptive to ointment vehicles. The thick keratin of the nail blocks absorption of topical agents. Treatment options A topical corticosteroid and/or topical calcipotriene (Dovonex) in a solution vehicle are recommended, along with daily use of a tar shampoo. For onycholysis, a topical corticosteroid in a solution vehicle may be used under the nail. Systemic therapy may be required to improve severe disease.

Nails

Genitalia The thin skin of the genitalia is highly A low-potency topical corticosteroid ointment is sensitive to the adverse effects recommended. Topical calcipotriene, which is not (atrophy) of topical corticosteroids. associated with a risk of atrophy, may be used. Palms and soles The thick stratum corneum of palms and soles is a barrier to penetration of topical agents. A highest-potency topical corticosteroid is recommended. Methotrexate (Rheumatrex) or acitretin (Soriatane; a systemic retinoic acid analog) may be needed.

TOPICAL CORTICOSTEROIDS

Topical corticosteroids are the most commonly prescribed treatment for psoriasis.5 They are available in ointment, cream, lotion and solution forms. Corticosteroids have well-recognized anti-inflammatory and antiproliferative effects, which are thought to be their primary mechanism of action in psoriasis.6 Topical steroids are classified as low-, medium-, high- and super-high potency agents (Table 2). In general, treatment is initiated with a medium-strength agent, and high-potency agents are reserved for the treatment of thick chronic plaques that are refractory to weaker steroids. Low-potency agents are used on the face, on areas where the skin tends to be thinner, and on the groin and axillary areas, where natural occlusion increases the potency of a low-potency agent to the equivalent of a higher potency agent. Use of highpotency agents in these areas increases the risk of side effects and therefore should be avoided. Potential side effects from corticosteroids include cutaneous atrophy, telangiectasia and striae, acne eruption, glaucoma, hypothalamus-pituitary-adrenal axis suppression and, in children, growth retardation. The true incidence of corticosteroid-induced hypothalamus-pituitary-adrenal suppression is unknown, but it is of concern with prolonged use.7 Often, evidence of hypothalamus-pituitary-adrenal axis suppression is found on the laboratory results, even when clinical symptoms are absent. Careful long-term follow-up of patients receiving topical corticosteroid therapy is highly recommended to detect potential complications. Although corticosteroids are rapidly effective in the treatment of psoriasis, they are associated with a rapid flare-up of disease after discontinuation, and they have many potential side effects. Consequently, topical corticosteroids are frequently used in conjunction with another agent to maintain control. Topical calcipotriene is often used in combination with topical corticosteroids to speed clearing of the lesions and maintain control after the initial phase of treatment is completed.
CALCIPOTRIENE

Calcipotriene is a vitamin D3 analog available in cream, ointment and solution formulations. It inhibits epidermal cell proliferation and enhances normal keratinization. This agent has a slow onset of action, and patients should be aware that the effects of calcipotriene may not be noticeable for up to six to eight weeks after the initiation of therapy.
www.aafp.org/afp/2000/0201/p725.html?printable=afp 7/12

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

Although calcipotriene monotherapy has been shown to be moderately effective in reducing the thickness, scaliness and erythema of psoriatic lesions,8 maximal benefits are achieved when calcipotriene is used in combination with potent topical corticosteroids. A simplified approach for combination therapy is to begin therapy with a quick-fix phase, followed by a transitional phase and then a maintenance phase.9 For example, treatment could be initiated with twice-daily applications of a topical corticosteroid and calcipotriene until the lesions are flat; the maximum duration of this phase is four weeks. When the lesions have become flat, therapy can then be changed to twice daily use of calcipotriene only, with corticosteroid pulse therapy twice daily on weekends only. This second phase helps prevent rebound from abrupt withdrawal of corticosteroids. When the lesions have remained flat and the intensity of their color has declined from bright red to pink, the maintenance phase begins, with use of calcipotriene alone and discontinuation of the weekend use of topical corticosteroids. After appropriate control of the disease is maintained, topical therapy can be discontinued until a flare-up occurs. Use of emollients should be recommended, to reduce the scaly appearance of the lesions and to potentially reduce the amount of corticosteroid needed. The only cutaneous side effect of calcipotriene is local irritation, which occurs in approximately 15 percent of patients.10 Calcipotriene is not recommended for use on the face or with occlusion. Hypercalcemia is a potential side effect of this agent when the dosage exceeds 100 g per week. This effect does not usually occur with weekly use of 100 g or less.11,12 Most reports of hypercalcemia have been in patients who received prolonged therapy with 200 g or more per week. For localized psoriasis, the recommended dosages do not require monitoring of serum or urinary calcium levels. However, calcipotriene should be used with caution in patients with compromised renal function or a history of renal calculi.
COAL TAR

Coal tar is a black viscous fluid that was first described by Goeckerman in 1925, when it was combined with ultraviolet light for the treatment of psoriasis. It is thought to suppress epidermal DNA synthesis.13 Coal tar is available as an ointment, cream, lotion, shampoo, bath oil and soap. Coal tar is most effective when it is used in combination with other agents, especially ultraviolet B light. Like calcipotriene, coal tar is effective when it is combined with topical corticosteroids. Coal tar shampoo can be used in combination with a corticosteroid scalp solution for the treatment of psoriasis on the scalp. Because coal tar is messy and malodorous and can stain clothing, nighttime application is recommended. Patients should be advised to use old bed linens and and to wear old pajamas when they are using coal tar. Tar products can cause folliculitis, but they otherwise are generally not associated with side effects.
ANTHRALIN

If good control of psoriasis is not achieved with topical corticosteroids, alone or in combination with calcipotriene or coal tar, consideration should be given to the addition of anthralin or tazarotene therapy. Anthralin, also known as dithranol, is an antipsoriatic topical preparation derived from wood tar.4 It has been available since 1916, but it is a second-line agent because of its irritating and staining properties. Anthralin is available in 0.1 percent to 1 percent ointments, creams and solutions. It is generally used on notably thick, large plaques of psoriasis, and therapy is initiated at low concentrations for short periods. The concentration and duration of contact with each treatment is gradually increased, up to a maximum of 30 minutes per application.4 Anthralin can be combined with ultraviolet phototherapy; this is known as the
www.aafp.org/afp/2000/0201/p725.html?printable=afp 8/12

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

traditional Ingram regimen. Patients should be warned that anthralin has a tendency to stain any surface, including the skin, clothing and bathtub. Its use should be limited to well-demarcated plaques, and it should be applied with a cotton-tipped applicator or a gloved hand. Patients should be warned that normal skin surrounding the psoriatic lesion may become irritated if it comes in contact with anthralin.
TAZAROTENE

Topical tazarotene is the first topical receptor-selective retinoid approved for the treatment of psoriasis. It is available only in gel form and exerts its effects through gamma and beta retinoic acid receptors. Tazarotene helps to normalize the proliferation and differentiation of keratinocytes, as well as to decrease cutaneous inflammation.14,15 Once-daily application of tazarotene gel, 0.05 percent or 0.1 percent concentration, has been shown to be as effective as twice-daily application of 0.05 percent fluocinonide cream.16 As monotherapy, tazarotene has been shown to significantly reduce plaque elevation in mild to moderate psoriasis.17 However, because of its modest efficacy, slow onset of action and high potential for causing irritation, tazarotene should usually be used in combination with corticosteroids. The primary side effect of topical tazarotene is minor skin irritation and increased photosensitivity. Tazarotene is classified as a pregnancy category X drug and its use should be avoided in women of childbearing age.
SUNLIGHT AND TANNING-BED TREATMENT

Sun exposure in addition to topical therapy may be beneficial when multiple areas are affected with psoriasis. Patients should be encouraged to obtain natural sunlight exposure or tanning-bed light exposure for a few minutes a day, and then to slowly increase the duration of exposure as tolerated. Unaffected areas should be covered with a sunscreen, especially the face. Ultraviolet light exposure can be used judiciously to prevent flare-ups during the maintenance phase of therapy.

Intralesional Injections, Phototherapy and Systemic Therapy

Psoriatic plaques that fail to respond to topical therapy may be improved by administration of intralesional corticosteroid injections. Triamcinolone (Kenalog) is often used for this purpose. The agent is injected directly into the dermis of a small, persistent plaque. The concentration is generally 3 to 10 mg per mL, depending on the size, thickness and area of the lesion. The dose of triamcinolone is released gradually over three to four weeks; additional injections may be needed every four to six weeks to improve the response. Disadvantages of intralesional injections include pain during the injection and potential side effects of local atrophy and systemic absorption. The patient with refractory lesions may benefit from more advanced forms of treatment, such as phototherapy (ultraviolet B alone or psoralens plus ultraviolet A), outpatient treatment at a clinic specializing in psoriasis and systemic therapy with oral retinoids, methotrexate (Rheumatrex) or cyclosporine (Sandimmune). Combination therapy has also been shown to be effective, especially phototherapy in combination with topical anthralin, coal tar or calcipotriene (Table 4).
TABLE 4.

Therapy for Generalized Psoriasis

Therapy Ultraviolet B (UVB) light Characteristics that guide the choice of therapy Used for many years, highly effective. May cause acute phototoxicity. Little to no longterm side effects. UVB can be used at home for maintenance therapy.
9/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

Psoralen plus ultraviolet A (PUVA) Retinoids (acitretin [Soriatane]) Methotrexate (Rheumatrex)

Highly effective; can be used as maintenance therapy. High risk of acute phototoxicity. Long-term risks include high risk of cutaneous malignancy. Moderately effective; best for pustular psoriasis. Potent teratogen; use in women of childbearing potential should be avoided. Causes dryness of skin. May cause elevation of triglycerides. Hyperostosis with long-term use. Highly effective and can be used on a long-term basis. Should not be used in noncompliant patients or when there is preexisting hepatic disease. Can cause acute or chronic hepatotoxicity, and acute neutropenia and pancytopenia.

Cyclosporine Highly effective. Careful monitoring required. The long-term risk of renal toxicity, which (Sandimmune) may not be detectable by blood tests, limits long-term use. Frequently used or well-studied combination therapies UVB plus topical calcipotriene (Dovonex) UVB plus topical coal tar PUVA plus topical calcipotriene PUVA plus retinoids Acitretin plus topical calcipotriene Cyclosporine plus topical calcipotriene Infrequently used or less well-studied therapies UVB plus methotrexate PUVA plus methotrexate

Goals of Therapy and When to Refer

In all cases, the therapeutic goal is to maximize treatment efficacy and the patient's quality of life, while minimizing side effects. Achieving and maintaining control of psoriatic lesions is the central goal in treatment. Physicians and patients need to understand that there is no definitive cure for psoriasis (Figure 4). Control of the disease may mean that lesions are not as thick or as red as they were before treatment, but some degree of erythema may remain. Most often, treatment does not result in complete clearing of the lesions.

FIGURE 4. A treated lesion of psoriasis. The goals of treatment for localized psoriasis include a decrease in the size and redness of the plaque, as well as a reduction in the amount of scale on the lesion. Compared with the lesion in Figure 2, this lesion is flat, and the scale is not obvious. It does retain mild redness. This is the result that should be expected in the treatment of localized psoriasis.

Although the algorithm serves as a guide to the treatment of localized psoriasis, various paths can be taken to achieve control of localized disease. The treatment path should be decided on a patient-to-patient basis. As
www.aafp.org/afp/2000/0201/p725.html?printable=afp 10/12

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

mentioned previously, generalized psoriasis may require more complex forms of therapy. Consultation with a dermatologist may be beneficial for patients who require such therapy.

The Authors
ASHA G. PARDASANI, M.D., is a dermatology resident at Wake Forest University School of Medicine, Winston-Salem, N.C. She is a graduate of West Virginia University School of Medicine, Morgantown. STEVEN R. FELDMAN, M.D., PH.D., is associate professor of dermatology and pathology at Wake Forest University School of Medicine, Winston-Salem, N.C. He graduated from Duke University School of Medicine, Durham, N.C., where he also received a doctorate degree. Dr. Feldman completed a dermatology residency at the University of North Carolina, Chapel Hill. He is a member of the editorial board of the Journal of the American Academy of Dermatology. ADELE R. CLARK, P.A.-C., is the coordinator of the Psoriasis Skin Treatment Center of the Department of Dermatology at Wake Forest University. She completed undergraduate training at the University of North Carolina, Chapel Hill, and physician assistant training at Emory University School of Medicine, Atlanta. Address correspondence to Asha G. Pardasani, M.D., Department of Dermatology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157. Reprints are not availab le from the authors. Dr. Feldman has received honoraria from Westwood-Squib b Pharmaceuticals and Glaxo Wellcome, Inc.; has served as a consultant for Allergan, Inc., Glaxo Wellcome, Inc., Ortho Pharmaceutical Corp., and Westwood-Squib b Pharmaceuticals; has received grant or research support from Glaxo Wellcome, Inc., Ortho Pharmaceutical Corp., and Westwood-Squib b Pharmaceuticals, and has served on the speakers b ureau for Allergan, Inc., and WestwoodSquib b Pharmaceuticals.

REFERENCES 1. Fleischer AB Jr, Feldman SR, Bradham DD. Office-based physician services provided by dermatologists in the
United States in 1990. J Invest Dermatol. 1994;102:937.

2. Fleischer AB Jr, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR, et al. Disease severity measures
in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol. 1996;107:269.

3. American Academy of Dermatology. Committee on Guidelines of Care, Task Force on Psoriasis. Guidelines of
care for psoriasis. J Am Acad Dermatol. 1993;28:6327.

4. Feldman SR. Psoriasis treatment. Curr Prob Dermatol. 1998;101140. 5. Lebwohl M, Abel E, Zanolli M, Koo J, Drake L. Topical therapy for psoriasis. Int J Dermatol. 1995;34:67384. 6. Gower WR Jr. Mechanism of glucocorticoid action. J Fla Med Assoc. 1993;80:697700. 7. Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical
steroids. J Am Acad Dermatol. 1993;29:5013.

8. Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, et al. Efficacy and safety of calcipotriol
(MC 903) ointment in psoriasis vulgaris: a randomized, double-blind, right/left comparative vehicle-controlled study. J Acad Dermatol. 2992;27 6 pt 19838.

9. Koo J. Sequential therapy for psoriasis. NPF Psoriasis Forum . 1998;4(2)3. 10. Kragballe K. Vitamin D3 analogues. Dermatol Clin. 1995;13:8359. 11. Kragballe K, Gjersten BT, De Hoop D, Karlsmark T, van de Kerkhof PC, Larko O, et al. Double-blind, right/left
comparison of calcipotriol and beta-methasone valerate in treatment of psoriasis vulgaris. Lancet. 1991;337:1936.

12. Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D, et al. Comparative study of calcipotriol
(MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol. 1992;265 pt 173643.

13. Camisa C. UVB phototherapy and coal tar. In: Camisa C, ed. Psoriasis. Boston: Blackwell Scientific, 1994:205
26.

14. Foster RH, Brogden RN, Benfield P. Tazarotene. Drugs. 1998;55:70511. 15. Duvic M, Asano AT, Hager C, Mays S. The pathogenesis of psoriasis and the mechanism of action of
www.aafp.org/afp/2000/0201/p725.html?printable=afp 11/12

4/09/12

www.aafp.org/afp/2000/0201/p725.html?printable=afp

tazarotene. J Am Acad Dermatol. 1998;394 pt 2S12933.

16. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Freidman DJ, Jegasothy BV, et al. Tazarotene gel, a new
retinoid for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997;37:8592.

17. Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, et al. The safety and efficacy of tazarotene
gel, a topical acetylenic retinoid, in the treatm of psoriasis. Arch Dermatol. 1998;134:5760. Copyright 2000 by the American Academy of Family Physicians. This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests. AFP Home | About Us | Contact Us | Subscribe/Renew | AFP by E-Mail | Permissions About Online Access | Employment Opportunities Information for: Authors | Advertisers

www.aafp.org/afp/2000/0201/p725.html?printable=afp

12/12